المؤلفون: Ramos-Suzarte M; Center of Molecular Immunology, Havana, Cuba. mayra@cim.sld.cu, Lorenzo-Luaces P, Lazo NG, Perez ML, Soriano JL, Gonzalez CE, Hernadez IM, Albuerne YÁ, Moreno BP, Alvarez ES, Callejo IP, Alert J, Martell JA, Gonzalez YS, Gonzalez YS, Astudillo de la Vega H, Ruiz-Garcia EB, Ramos TC

المصدر: Cancer biology & therapy [Cancer Biol Ther] 2012 Jun; Vol. 13 (8), pp. 600-5. Date of Electronic Publication: 2012 Jun 01.

نوع المنشور: Clinical Trial, Phase II; Journal Article

بيانات الدورية: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101137842 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1555-8576 (Electronic) Linking ISSN: 15384047 NLM ISO Abbreviation: Cancer Biol Ther Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Monoclonal, Humanized/*therapeutic use , Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Esophageal Neoplasms/*drug therapy, Antibodies, Monoclonal, Humanized/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Combined Modality Therapy ; ErbB Receptors/antagonists & inhibitors ; ErbB Receptors/genetics ; Esophageal Neoplasms/radiotherapy ; Female ; Humans ; Male ; Middle Aged ; Treatment Outcome